Genentech, a member of the Roche Group, exhibited its evident enthusiasm for AC Immune SA's pipeline of antibodies in development for Alzheimer's disease, by in-licensing the company's preclinical tau-targeting program in a deal potentially worth upward of CHF400 million (US$421 million) in up-front plus research, development and sales-associated milestone payments.